Lightbridge (LTBR) Q2 2026 earnings summary

Executive summary

• Achieved a key milestone with removal of initial fuel material samples from the Advanced Test Reactor at Idaho National Laboratory in May 2026, with post-irradiation examination expected later this year.

• Integrated Lightbridge Fuel design into widely used commercial core management software through a partnership with Studsvik Scandpower.

• Advanced domestic supply chain efforts by signing a memorandum of understanding with Quadrant Nuclear Industries for future high-assay, low-enriched uranium supply.

• Reconstituted Nuclear Utility Fuel Advisory Board in June 2026 to guide commercialization and development priorities.

• Secured new patents in the US and Europe for advanced nuclear fuel designs and manufacturing methods.

Financial highlights

• Cash and cash equivalents rose to $237.5M as of June 30, 2026, up from $201.9M at year-end 2025.

• Net loss for Q2 2026 was $5.8M, compared to $3.5M in Q2 2025; six-month net loss was $12.1M, up from $8.3M year-over-year.

• R&D expenses for Q2 2026 were $4.0M, up from $1.6M in Q2 2025; six-month R&D expenses were $7.3M, up from $3.3M.

• G&A expenses for Q2 2026 were $3.7M, up from $2.5M; six-month G&A expenses were $8.0M, up from $6.0M.

• Other income for H1 2026 was $3.2M, up from $1.0M in H1 2025, primarily from interest income on higher cash balances.

Outlook and guidance

• Post-irradiation examination of fuel samples to begin later in 2026, providing critical data for licensing and performance modeling.

• Sufficient liquidity to fund operations for at least 12 months; long-term funding needs will require additional equity, partnerships, or government support.

• Expects R&D and capital expenditures to rise as pilot-scale facility and commercialization efforts progress.

• Ongoing evaluation of funding opportunities, including strategic partnerships, government grants, and capital market transactions.

• Uncertainties remain regarding timing and cost of commercialization, dependent on technical, regulatory, and market factors.